Abstract
Background
Lyme disease is the most prevalent tick-borne disease in the USA with the highest number of cases (27 444 patients) reported by CDC in the year 2007, representing an unprecedented 37% increase from the previous year. The haematogenous spread of Borrelia burgdorferi to various tissues results in multisystemic disease affecting the heart, joints, skin, musculoskeletal and nervous system of the patients.
Objectives
Although Lyme disease can be effectively treated with doxycycline, amoxicillin and cefuroxime axetil, discovery of novel drugs will benefit the patients intolerant to these drugs and potentially those suffering from chronic Lyme disease that is refractory to these agents and to macrolides. In this study, we have explored 5′-methylthioadenosine/S-adenosylhomocysteine nucleosidase as a drug target for B. burgdorferi, which uniquely possesses three genes expressing homologous enzymes with two of these proteins apparently exported.
Methods
The recombinant B. burgdorferi Bgp and Pfs proteins were first used for the kinetic analysis of enzymatic activity with both substrates and with four inhibitors. We then determined the antispirochaetal activity of these compounds using a novel technique. The method involved detection of the live–dead B. burgdorferi by fluorometric analysis after staining with a fluorescent nucleic acids stain mixture containing Hoechst 33342 and Sytox Green.
Results
Our results indicate that this method can be used for high-throughput screening of novel antimicrobials against bacteria. The inhibitors formycin A and 5′-p-nitrophenythioadenosine particularly affected B. burgdorferi adversely on prolonged treatment.
Conclusions
On the basis of our analysis, we expect that structure-based modification of the inhibitors can be employed to develop highly effective novel antibiotics against Lyme spirochaetes.
Keywords: Lyme disease, enzyme inhibitors, Bgp, fluorometric assay, spirochete
Introduction
Lyme disease, caused by the spirochaete Borrelia burgdorferi, is the most prevalent tick-borne multisystemic illness and affects the heart, joints, skin, musculoskeletal and nervous system. Persistent infection with the spirochaete results in potentially incapacitating arthritis, neuroborreliosis, acrodermatitis chronicum atrophicans and carditis. Doxycycline, amoxicillin or cefuroxime axetil are recommended as the first-line therapy for early and late Lyme disease. Macrolides are less effective against B. burgdorferi,1,2 and resistance of these spirochaetes to erythromycin has been reported.3 As a result, macrolides, including azithromycin, clarithromycin and erythromycin, are recommended only for patients intolerant to the first-line therapy. Hence, discovery of new antimicrobials that could be used alone or in combination with other antibiotics will be highly beneficial for drug-intolerant patients and potentially for patients suffering from chronic Lyme disease that is refractory to other agents.
One potential drug target that has been identified is the enzyme 5′-methylthioadenosine/S-adenosylhomocysteine (MTA/SAH) nucleosidase,4 an enzyme present in most bacterial species but absent in humans. MTA/SAH nucleosidase cleaves the glycosidic linkage of the nucleosides to generate the thiosugars 5-methylthioribose (MTR) or S-ribosylhomocysteine (SRH) and the purine adenine.5 In bacteria, MTA is produced from S-adenosylmethionine (SAM) as a by-product of polyamine, autoinducer I and biotin synthesis, while SAH is derived from SAM-mediated methylation reactions. MTR and SRH can be salvaged through separate routes to methionine, while adenine re-enters the purine pools of the cell. Cleavage of SRH by the enzyme LuxS yields homocysteine, which can be remethylated to methionine, and 4,5-dihydroxy-2,3-pentanedione (DPD), a precursor for autoinducer-2 (AI-2) synthesis. Thus, the activity of the nucleosidase is connected to the production of two bacterial quorum-sensing autoinducers.6–8 These autoinducers are involved in the induction of various virulence factors in bacteria and contribute to their pathogenesis.6–8
Nucleosidase inhibitors could exert antimicrobial actions by one or more mechanisms and have been explored as a target for the design of the broad-spectrum antibiotics against Gram-positive and Gram-negative bacteria by several laboratories.4,9–15 MTA and SAH are known to inhibit polyamine synthase16,17 and methyltransferase18 activities in various organisms. Thus, inhibition of the nucleosidase could work by promoting a build-up of MTA and SAH to growth-inhibitory levels. In addition, the loss of salvage of purine and methionine components may suppress bacterial growth by nutrient limitation, and because it is energetically expensive to make methionine de novo.
Due to the absence of major biosynthetic pathways, it is particularly important for the nutritional auxotroph, B. burgdorferi, to recycle metabolic by-products. However, Borrelia species lack methionine synthase (metH), which is required to remethylate homocysteine to methionine, and do not have a functional mtnK gene (methylthioribose kinase) required to salvage methionine from MTR.19 Loss of adenine salvage by nucleosidase inhibition may have a significant effect on B. burgdorferi, since they are purine auxotrophs. Alternatively, interruption of the synthesis of SRH and DPD, and subsequent loss of AI-2 signalling may represent a unique aspect of nucleosidase inhibitors7,20 as Lyme spirochaetes are known to synthesize AI-2 and alter surface protein expression in response to this autoinducer.21,22
Previously, we identified a glycosaminoglycan-binding protein located on the surface of B. burgdorferi and named it Borrelia glycosaminoglycan-binding protein or Bgp.23 Interestingly, Bgp is homologous to the cytoplasmic Pfs protein present in a wide variety of bacterial species and also exhibits MTA/SAH nucleosidase activity.24 The genome sequence of B. burgdorferi shows the presence of three Pfs homologues: Pfs (BB0375), Bgp (BB0588) and MtnN (BBI06).25 The translated sequences for bgp and plasmid-borne mtnN genes contain predictable signal peptides, indicating that they are potentially exported proteins.23 Indeed, we have shown that Bgp is a surface protein and its sequence analysis showed that the mature Bgp protein lacks the signal peptide.23 Synthesis of MtnN and its cellular localization and enzymatic activity have not yet been determined. The cytoplasmic Pfs in the Lyme spirochaetes also exhibits MTA/SAH nucleosidase activity24 and is a part of the four-gene (BB0374-pfs-metK-luxS) operon encoding proteins involved in the synthesis of the quorum-sensing molecule, AI-2. Lyme spirochaetes are the only known bacteria in which more than one copy of nucleosidase genes are present, with two gene products apparently exported.25 The B. burgdorferi genome is rather small (1.52 Mb), and is approximately one-third of the size of the Escherichia coli genome (4.6 Mb). The presence of multiple MTA/SAH nucleosidases suggests that the enzymes are important for Lyme disease spirochaetes. Since B. burgdorferi lacks a majority of the biosynthetic pathways, MTA/SAH nucleosidases could play a critical role in the salvage of the purine adenine from MTA and SAH that is derived from both pathogen and host metabolisms. B. burgdorferi is likely to recycle this macromolecule building block more efficiently due to the presence of MTA/SAH nucleosidase enzymes both in the cytoplasm and on the spirochaete surface. Therefore, this enzyme offers us a unique opportunity to explore substrate analogues as antimicrobials against this important human pathogen.
The slow growth and unreliable colony formation ability of B. burgdorferi on solid media makes traditional plating methods unsuitable to screen and assess the effect of antimicrobials on spirochaete viability. Therefore, we have developed here a fluorescence-based high-throughput screening system involving a combination of Hoechst 33342 and Sytox Green nucleic acid stains to distinguish total and dead spirochaetes, respectively. Sytox Green is excluded by the plasma membrane of live organisms, and hence it stains nucleic acids of only the dead or physiologically compromised microbes.26,27 A direct correlation was observed between Sytox Green staining and the proportion of dead spirochaetes in the sample. After comparing the activities of four MTA/SAH nucleosidase inhibitors on recombinant B. burgdorferi Bgp and Pfs proteins, we determined the effects of these compounds on spirochaete growth by employing this nucleic acid stain combination. Lastly, structure-based modelling was used to visualize potential interactions of MTA analogues with B. burgdorferi nucleosidases and to predict modifications that may lead to more selective and potent antiborrelial agents.
Materials and methods
Bacterial strains and culture
B. burgdorferi isolate B314, a high-passage, non-infectious derivative of the infectious B31 strain, which has lost all endogenous plasmids except cp26 and cp32, and an infectious strain N40 clone D10/E9 were used in this study. Since the lp28-4 plasmid possessing the mtnN gene is missing in B314, this isolate can only express Pfs and Bgp while the infectious N40 strain can possibly express all three genes, pfs, bgp and mtnN. The spirochaetes were grown at 33°C in BSK II medium containing 6% rabbit serum to a density of 108 spirochaetes/mL for each assay. To study the effect of inhibitors and ampicillin on the growth of B. burgdorferi, cultures were grown in a 5% CO2 incubator at 37°C.
Assessment of the fluorescence-based system in high-throughput screening of live–dead B. burgdorferi
B. burgdorferi cultures were grown to a density of ∼108 spirochaetes/mL and divided into two aliquots. One aliquot was incubated at 60°C for 30 min to kill the spirochaetes. A 10-fold serial dilution of dead B. burgdorferi was prepared in remaining live bacterial suspension such that the ratio of live spirochaetes decreased from 100% to 0% and dead spirochaetes increased from 0% to 100% (i.e. 100:0 to a final 0:100 ratio of live–dead B. burgdorferi). Two hundred microlitres of culture mixture was transferred to each well of a 96-well black plate with a clear bottom (Catalog number 3603, Corning Incorporated, NY, USA). Two microlitres of a 1:1 mixture of 5 µM Sytox Green and 10 µM Hoechst 33342 was added to each well. After mixing, the plate was incubated at 37°C for 1–2 h and the Sytox Green (extinction 504 nm/emission 523 nm) and Hoechst 33342 (extinction 350 nm/emission 461 nm) fluorescences were measured using a Spectramax M2 spectrophotometer/microplate reader (Molecular Devices, CA, USA). The ratio of the fluorescence emission due to Sytox Green binding to nucleic acids determined the presence of dead spirochaetes and staining with Hoechst, which estimated both live and dead B. burgdorferi in the sample, provided the net fluorescence due to the dead spirochaetes. The standard curve between the known percentage of dead spirochaetes and net Sytox Green fluorescence for B314 and N40 strains was prepared to determine the sensitivity of detection of dead non-infectious versus infectious B. burgdorferi strains. Six replicates were used for each treatment and each experiment was repeated at least three times to confirm the reproducibility of the assay.
For fluorescence microscopy, the spirochaetes were centrifuged after incubation with the stain mixture, washed once with PBS and mounted in a 1:1 PBS/glycerol mixture. Sealing with nail polish limited the evaporation and prevented movement of the cover glasses. Differential interference contrast (DIC) provision in the Nikon 80i fluorescence microscope was used to observe total spirochaetes present in any field of view. DAPI (for Hoechst 33342 staining) and FITC (for Sytox Green staining) filters were used with ×100 magnification Apo-Plan TIRF objective to examine whether total spirochaetes observed by DIC are also visualized by Hoechst staining and whether physiologically compromised spirochaetes are detectable by Sytox Green staining.
Effect of ampicillin on B. burgdorferi growth
Lyme disease is treated with penicillin, tetracycline and cephalosporin classes of antibiotics.1,2 Therefore, the efficacy of the fluorescence-based assay system was first assessed using ampicillin treatment of B. burgdorferi. Ten 2-fold dilutions of ampicillin were prepared starting from 200 µg/mL. Ten microlitres of each antibiotic dilution was added to 190 µL of B. burgdorferi culture in each of the six replicate wells of the 96-well black plate to obtain final concentrations of ampicillin from 10 to 0.0195 µg/well. After mixing for 5 min, the plate was incubated overnight at 37°C with 5% CO2. The Sytox Green and Hoechst 33342 mixture was then added to each well, mixed, incubated for 1–2 h at 37°C and the fluorescence measured as described earlier. A standard prepared with known live–dead B. burgdorferi mixtures was used to calculate the percentage of dead/killed spirochaetes present in each treated sample.
Examination of substrate and inhibitor activity for B. burgdorferi MTA/SAH nucleosidases, Bgp and cytoplasmic Pfs
Unlike other bacteria, B. burgdorferi contains cytoplasmic (Pfs) and homologous cell surface proteins (Bgp and probably also MtnN), with at least Bgp and Pfs showing MTA/SAH nucleosidase activity.24 For the present study, recombinant His-tagged Bgp and Pfs were expressed and purified as previously described.24 The concentrations of recombinant Bgp and Pfs were determined using a Cary 100 scanning UV/Visible spectrophotometer (Varian, Palo Alto, CA, USA), and absorbance 280 (0.1%) values of 0.705 (Bgp) and 0.487 (Pfs). Enzyme activity was studied using a UV assay that follows the drop in absorbance at 275 nm that accompanies the conversion of the nucleoside into adenine and the corresponding thiosugar.28,29 Specific activity measurements employed reaction mixtures containing 100 µM nucleoside and 100 mM sodium phosphate buffer at the optimized pH for each enzyme (pH 7 for Bgp; pH 5 for Pfs). Substrate nucleosides (MTA and SAH) and the inhibitor formycin A (FMA) were obtained from Sigma (St Louis, MO, USA). The inhibitors 5′-p-nitrophenylthioadenosine (pNO2PhTA) and 5′-p-aminophenylthioadenosine (pNH2PhTA) were gifts from Drs M. K. Riscoe and R. W. Winter (Veterans Affairs Medical Center, Portland, OR, USA). The transition-state analogue, BnT-DADMe-ImmA, was a gift from Drs Y. S. Babu and J. Zhang (BioCryst Pharmaceuticals, Birmingham, AL, USA). Conversion of substrate into adenine was calculated using an extinction coefficient (275 nm) for nucleoside decay of 1.6 mM−1cm−1. Concentrations of nucleosides were estimated by UV absorbance at 260 nm and an extinction coefficient of 15 400 M−1cm−1. Reactions were initiated by the addition of 1–2 µg of enzyme and followed for 20–30 min at 22°C. For the determination of kinetic constants, substrates (MTA or SAH) were tested from 1 to 100 µM, with at least triplicate measurements performed at each concentration. Kinetics data were fitted to the Michaelis–Menten equation using Igor Pro 5.0 (Wavemetrics, Lake Oswego, OR, USA). Enzyme inhibition was analysed using the UV assay, with varying concentrations of the inhibitor (10–500 nM for BnT-DADMe-ImmA; 1–10 µM for pNO2PhTA and pNH2PhTA; and 25–250 µM for FMA) incorporated into reactions containing 100 µM MTA.29 Controls having either no enzyme or no inhibitor were included in all experiments. The inhibition constant (Ki) was obtained by fitting the initial rate and inhibitor concentration to an equation for competitive inhibition:
where V0′ and V0 are the initial rates of the inhibited and uninhibited reactions, respectively, [I] the inhibitor concentration and [S] the concentration of MTA.29
Assessment of the selected inhibitors of MTA/SAH nucleosidase as antimicrobials against B. burgdorferi
Four MTA/SAH nucleosidase inhibitors, FMA, pNO2PhTA, pNH2PhTA and BnT-DADMe-ImmA, were selected on the basis of the results of an in vitro assay with purified B. burgdorferi Bgp and Pfs proteins. Fivefold serial dilutions of each of the inhibitors were prepared from 200 to 0.32 µM (final concentrations of 10–0.016 µM). Four replicates of each treatment were used. The experiment was conducted as described earlier for ampicillin, and fluorometric and microscopic observations taken. To distinguish the bacteriostatic versus bactericidal activities of the inhibitors, the plate was incubated for 7 days. An aliquot of 2 µL of culture from each well was transferred to 1 mL of BSK II medium containing rabbit serum, to allow viable spirochaetes in the sample to recover and grow. After 14–21 days of incubation of culture tubes without inhibitors at 33°C, the presence of viable, motile spirochaetes was recorded using a dark-field microscope.
Modelling studies
High homology between B. burgdorferi MTA/SAH nucleosidase sequences and the corresponding E. coli enzyme (which has several solved crystal structures) and complete conservation of active site residues involved in catalysis were used in preliminary modelling studies to generate three-dimensional structures for Bgp and Pfs that might be instructive for future drug design. Initial models were created using the structural coordinates for E. coli nucleosidase containing bound FMA (PDB accession no. 1NC3A). Sequence threading was accomplished using the program SWISS-Model and sequence overlays were further refined using ViewerPro 4.2 (Accelerys).30–32
Results
Sensitivity of detection of dead or dying B. burgdorferi by Sytox Green stain
Spirochaetes killed by heating at 60°C for 30 min were used to generate a standard curve between relative fluorescence (Sytox/Hoechst) and known percentage of dead/physiologically compromised B. burgdorferi cells. In this assay, the green fluorescence of B. burgdorferi isolate B314 (Figure 1a) showed a high co-efficient of correlation (r2 = 0.962) with dead bacteria, indicating that staining of the nucleic acids by Sytox Green only occurs when viability of the spirochaetes is affected. Sensitivity of detection using Sytox Green stain was 10% dead spirochaetes since the assay could detect this level of killed B. burgdorferi reproducibly. The fluorescence values obtained using Hoechst 33342 DNA stain among different treatments within an experiment showed a standard deviation of <4% (data not shown). These results indicate that the total proportion of bacteria (live plus dead) in each sample, as detected by Hoechst staining, was accurately determined among different treatments, offering it to be a valuable control to assess consistency in spirochaete number in this assay system.
IC50 determination of ampicillin against B. burgdorferi using fluorescence-based assay system
Non-infectious B. burgdorferi isolate B314 was treated with 2-fold serial dilutions of ampicillin starting with 10 µg/200 µL of culture per well for 24 h. Determination of net Sytox Green fluorescence by fluorometric analysis indicated that similar to the heat-killed bacteria, B. burgdorferi were also unable to exclude this nucleic acid stain after treatment with ampicillin (Figure 1b). The IC50 of ampicillin calculated from the graphs (Figure 1a and b) was 0.35 µg per well or 1.75 µg/mL of B314 culture.
A similar analysis of the B. burgdorferi N40 strain (Figure 1c) showed that Sytox Green stain could distinguish dead and infectious spirochaetes as well. Again, a high coefficient of correlation (r2 = 0.978) was observed between the known percentage of dead N40 spirochaetes present in a sample and net Sytox Green fluorescence values (Figure 1c). Furthermore, IC50 for ampicillin against N40 strain is equivalent to that for the B314 isolate, i.e. 1.75 µg/mL of culture (Figure 1b–d), indicating that this stain can detect dead non-infectious and infectious Lyme spirochaetes indistinguishably. Therefore, only the infectious N40 strain clone D10/E9 was used for all further experiments.
For further validation of our assay, we examined the spirochaetes using fluorescence microscopy. As predicted, all spirochaetes present in a field of view were visible by both DIC microscopy as well as by Hoechst staining (Figure 2). However, only spirochaetes treated with heat (60°C) showed bright green fluorescence using the FITC filter due to the nucleic acids staining with Sytox Green. Bleaching of the stains was very quick for B. burgdorferi treated with ampicillin, probably due to the beginning of DNA degradation, and was not suitable for photomicroscopy (data not shown).
Kinetic analysis of MTA/SAH nucleosidase substrate analogues with purified recombinant Bgp and Pfs proteins
Specific activity measurements performed at saturating levels of MTA or SAH confirmed that both Bgp and Pfs are dual-substrate-specific enzymes. Freshly prepared Bgp and Pfs exhibited specific activities for MTA of 4.1 and 4.4 U/mg enzyme and for SAH 3.1 and 3.7 U/mg, respectively (Table 1), indicating that each of the preparations contained similar levels of active enzyme. The nucleoside analogue, pNH2PhTA, was a very poor substrate for Bgp (0.2 U/mg) and Pfs (0.024 U/mg), with no substrate activity detected at concentrations <50 µM (data not shown). The analogue pNO2PhTA was a slightly better substrate for Pfs (2.0 U/mg) than for Bgp (0.83 U/mg), but here as well, detectible substrate activity <20 µM was unreliable. As expected, FMA and BnT-DADMe-ImmA were not cleaved due to the absence of a hydrolysable glycosidic linkage. A summary of the results of kinetic analysis of substrate and inhibitor activities is found in Figure 3. For the two enzymes, only the differences in activity against MTA and FMA were statistically significant (P < 0.01; Student's t-test). The differences in activity between the two enzymes towards SAH, pNO2PhTA, pNH2PhTA and BnT-DADMe-ImmA were not significant (P > 0.05), suggesting that each enzyme recognizes bulkier 5′ substitutions in compounds to similar levels. Of the inhibitors tested, BnT-DADMe-ImmA (Ki = 2.3–3.4 nM) showed the tightest binding to the nucleosidases with Ki values roughly two to three orders of magnitude smaller than the Michaelis constant (Km) values reported for MTA (Km = 0.7–5 µM) and SAH (Km = 1.2–1.6 µM). This result is expected, since BnT-DADMe-ImmA is a transition-state analogue, and belongs to a class of compounds that have previously been reported to show picomolar and femtomolar dissociation constants for the E. coli nucleosidase.29
Table 1.
Enzyme | Compound | Specific activity (U/mg) | Relative activity (%) |
---|---|---|---|
Bgp | MTA | 4.1 | 100 |
SAH | 3.1 | 76 | |
pNH2PhTA | 0.2 | 5 | |
pNO2PhTA | 0.82 | 20 | |
FMA | 0 | 0 | |
BnT-DADMe-ImmA | 0 | 0 | |
Pfs | MTA | 4.4 | 100 |
SAH | 3.7 | 84 | |
pNH2PhTA | 0.024 | 0.6 | |
pNO2PhTA | 2.0 | 45 | |
FMA | 0 | 0 | |
BnT-DADMe-ImmA | 0 | 0 |
Enzyme activities were tested using the UV spectrophotometric assay (275 nm) and either 100 µM substrate (MTA and SAH) or 100 µM substrate analogue (pNH2PhTA, pNO2PhTA, FMA and BnT-DADMe-ImmA).
With the exception of FMA, where the Ki (1.05 and 2.69 µM) was less than the 10 µM reported for the E. coli enzyme,10 the inhibitors generally showed somewhat less activity towards the spirochaetal enzymes. For the late transition-state analogue BnT-DADMe-ImmA, the Ki value is substantially higher for Bgp (2.3 nM) and Pfs (3.4 nM) than that reported for E. coli nucleosidase (28 pM),29 although it is similar to that reported for the Streptococcus pneumoniae enzyme (5 nM).20
High-throughput screening of different inhibitors of MTA/SAH nucleosidase on the growth of B. burgdorferi
Based upon the kinetic analysis with purified recombinant Bgp and Pfs of B. burgdorferi (Figure 3), we assessed the inhibitory activities of all four compounds against the infectious spirochaete strain N40. The Hoechst/Sytox Green stain mixture was used to evaluate total and physiologically compromised B. burgdorferi, respectively. Calculation of the net Sytox Green fluorescence values (Sytox Green/Hoechst) after treatment with the inhibitors was followed by the determination of the bacteriostatic/dead bacteria present in the samples using the standard in Figure 1(c) to evaluate the inhibitory activities of these compounds. The results obtained with pNH2PhTA and BnT-DADMe-ImmA indicate that even at a relatively high concentration (10 µM), these inhibitors only partially affected the physiological status of the spirochaetes (Figure 4). However, the fluorometric assay suggested that both pNO2PhTA and FMA are highly effective inhibitors against B. burgdorferi. The MIC of these two inhibitors is lower than the least concentration tested here (0.016 µM) as detected by fluorometric analysis (Figure 4).
The effectiveness of this fluorometric assay system and potency of these inhibitors were further confirmed by microscopic examination of the samples. Indeed, microscopic examination after treatment confirmed the presence of dead or dying spirochaetes, as stained by Sytox Green (Figure 5). The staining was not as intense and uniform for the spirochaetes as observed by Sytox Green staining of the heat-killed spirochetes (Figure 2). However, fewer spirochaetes treated with pNH2PhTA and BnT-DADMe-ImmA (average of 43.8 ± 4.0% and 45.1 ± 3.1%, respectively, from 10 different fields) were visualized by Sytox Green staining when compared with those detected by Hoechst staining or DIC microscopy, while most spirochaetes stained with Sytox Green (average of 68.6 ± 4.2% from 10 fields) after treatment with pNO2PhTA, complementing our results from fluorometric analysis. Exclusion of Sytox Green by several spirochaetes after FMA treatment (only an average of 51.3 ± 5.5% stained with Sytox Green) was surprising. Hence, pNO2PhTA appears to be most effective against B. burgdorferi also by microscopic examination.
MTA/SAH substrate analogues show either bacteriostatic or bactericidal activities against infectious B. burgdorferi N40 strain
To examine whether the inhibitory activities of the four substrate analogues against spirochaetes have bactericidal or bacteriostatic effects, we recovered small aliquots (2 µL) from the treated samples daily and cultured B. burgdorferi in BSK II medium containing 6% rabbit serum without inhibitors. After treatment with all four compounds up to 4 days, at least some spirochaetes survived even after exposure to 10 µM (data not shown). However, we were unable to recover live spirochaetes when the N40 strain was treated with a higher concentration of FMA for 7 days. The recovery of spirochaetes was also poor after treatment with pNH2PhTA. Such a subtle distinction between the three inhibitors was not possible with the fluorometric analysis. In these studies, FMA appears to be bactericidal against B. burgdorferi after prolonged treatment while the other three MTA nucleosidase inhibitors could be bacteriostatic under the tested concentrations.
Modelling studies of Bgp and Pfs with FMA
The availability of a crystal structure of the E. coli MTA/SAH nucleosidase33 with FMA bound in the active site allowed preliminary predictions of the three-dimensional features of Bgp and Pfs to be made using modelling programs (Figure 6a). Ribbon threading of the B. burgdorferi Pfs (in blue) onto the known E. coli enzyme structure (in yellow) predicts very similar structures without additional energy minimizations. Threading the Bgp enzyme (in pink) onto the E. coli enzyme also predicted highly similar structures, although a less organized loop structure was suggested in the model to replace regions of alpha helices found in Pfs. Surface charges and the orientation of the 5′-hydroxyl group (O5 in Figure 6b) facing out of the active site pocket supports the availability of the 5′ position of the nucleoside for modification. From the model, the purine-binding pocket is predicted to be more restricted in Pfs than Bgp.
Active site residues involved in catalysis (E12, E174 and D197) are strictly conserved in Bgp (E34, E209 and D232) and Pfs (E11, E181 and D204). As expected, the highly homologous cytoplasmic E. coli nucleosidase and Pfs are suggested to have essentially the same secondary and tertiary structure in the model. Of note, the Bgp backbone is predicted to loop away from the other two strands at a juncture between β8 and α4 (yellow arrow in front view) in a region that provides a face for the purine-binding site. As shown in Figure 6(b), modelling of the electrostatic surface charges suggests that this divergence has the effect of orienting the phenyl ring of F187 in Bgp outward from the active site. By comparison, F158 of Pfs (F151 in E. coli) shields the active site and forms stabilizing aromatic interactions with the adenine ring of the substrate.13,20 Other small changes in the identity and position of residues around the entrance to the active site of Bgp are suggested as well in Figure 6(b). A replacement of Pfs F215 (E. coli F207) with slightly rotated Y243 in Bgp would predict a decrease in apparent shielding of N7 of the purine ring, while a substitution of Pfs I53 (I50 in E. coli) with V79 in Bgp suggests an increase in the accessibility of the bottom of the pocket.
Discussion
Limiting factors for the treatment of patients to curtail certain bacterial diseases are the incessant emergence of antibiotic resistance among various pathogens and intolerance of some patients against certain antibiotics.2,34 These often lead to the employment of a combination regimen of drugs for treatment. Alternatively, relatively less effective drugs are included in the treatment of drug-intolerant patients. Therefore, there is an urgent need to explore novel physiological inhibitors as the potential antimicrobials against bacterial pathogens, including B. burgdorferi. Success of the enzymatic inhibitors as antimicrobials depends on: (i) their ability to selectively restrict the growth of the pathogens without interfering with the human enzymes; and (ii) their broad effectiveness against various pathogens. In this study, we have examined substrate analogues of MTA/SAH nucleosidase enzymes of B. burgdorferi as potential antimicrobials.
Two activities of nucleosidase, cleavage of MTA and SAH, are carried out by two different enzymes in mammals, MTA phosphorylase and SAH hydrolase.35 While mammalian SAH hydrolase and bacterial MTA/SAH nucleosidase are not structurally similar, the crystal structures of the mammalian MTA phosphorylase enzyme and MTA/SAH nucleosidase of E. coli show significant similarities. A comparison of their active sites shows remarkable similarities in the residues involved in adenine binding, although the pocket enclosing N5 appears to be more open in the mammalian enzyme.13 Significant structural differences exist in the ribose-binding site between the two enzymes, where phosphate-binding amino acid residues in MTA phosphorylase, Arg and Thr, are replaced by Ser and Gly in the bacterial nucleosidase, hence preventing the charge–charge interactions.13,14 Importantly, the channel containing the 5′-alkylthio group of the MTA/SAH nucleosidase appears more open than in the mammalian enzyme, thus providing an explanation for the dual substrate specificity of the bacterial enzyme. Interactions between residues from the second chain of the nucleosidase dimer and the extended 5′-alkylthio group of SAH may provide additional stabilization and recognition.15
The models of B. burgdorferi proteins, while suggestive, should not be overinterpreted in the absence of true crystallographic evidence. The differences seen between the Km values for MTA between Bgp (5 µM) and Pfs (0.7 µM) may be explained by the small structural differences suggested in the models. These activity differences could also represent differences in the behaviours of the recombinant enzymes and conditions under which the assays were conducted. Prior evidence24 supported a lower Bgp Km for MTA (1.2 µM), which was more in line with the submicromolar values found for Pfs and the E. coli nucleosidase, but that assay followed the conversion of radioactive MTA into MTR, rather than direct spectrophotometric observance of substrate conversion that is reported here. In either case, the Km values reported here for both enzymes for MTA and SAH are similar to the values in the literature for the E. coli and Klebsiella nucleosidases28,36,37 and roughly an order of magnitude lower than those recently reported for S. pneumoniae nucleosidase.20
Taking advantage of the suggested structural similarities of MTA/SAH nucleosidases, we first conducted kinetic analysis of four previously examined inhibitors,13,15,36,38,39 with the purified recombinant Bgp and Pfs proteins followed by their evaluation with intact B. burgdorferi. Fluorometric analysis of the effect of MTA/SAH nucleosidase inhibitors on B. burgdorferi facilitated the identification of pNO2PhTA and FMA as more effective compounds against the spirochaetes. Interestingly, the IC50 of these inhibitors in damaging the plasma membrane integrity is much lower than that reported for the purified E. coli enzyme previously36,40 as well as shown here (Figure 3) for purified B. burgdorferi nucleosidases. These results suggest that MTA/SAH nucleosidase could be an even better target of the substrate analogues as antimicrobials in B. burgdorferi than other bacterial pathogens. This is likely due to the additive effect of these inhibitors on all three spirochaete enzymes in the intact organisms. In addition, B. burgdorferi may be more permeable to these inhibitors when compared with Gram-negative bacteria since their outer membrane lacks lipopolysaccharide and is more flexible. FMA showed a significant bactericidal activity against B. burgdorferi after prolonged treatment. Interestingly, pNH2PhTA, and not pNO2PhTA, seems to result in a significant level of killing of the spirochaetes at high dose (10 µM) on prolonged treatment, as detected by cultivation in the absence of an inhibitor. Such a subtle distinction between the inhibitors’ activities was not possible with the fluorometric, and even microscopic, analysis. In a human bone marrow cell growth assay, both pNH2PhTA and pNO2PhTA showed low toxicity, with IC50 values >100 µM (K. A. C., unpublished data), suggesting that their toxicity to B. burgdorferi is selective.
In summary, we have developed a novel high-throughput, fluorometric screening method for B. burgdorferi viability after treatment with the potential antimicrobials, and have assessed its effectiveness using MTA/SAH nucleosidase as a target. After characterization of the inhibitors in our collection using purified recombinant B. burgdorferi nucleosidase, we further used this fluorometric method, as well as analysis by microscopy and culture to assess the potency of these inhibitors as antimicrobials. We report here that pNO2PhTA and FMA have high inhibitory activities on B. burgdorferi even at very low concentrations (0.016 µM). In addition, FMA is potentially bactericidal when treatment is extended to 7 days. These results indicate that the MTA/SAH nucleosidase enzyme is an excellent target for the discovery of new antimicrobials against Lyme disease spirochaetes. This study further supports potential use of novel inhibitors against this critically important enzyme for the treatment of Lyme disease in the future, especially when patients are intolerant to doxycycline, amoxicillin or cefuroxime axetil, for pregnant women or potentially for patients suffering from chronic Lyme disease. We will examine other substrate analogues for this enzyme as well as attempt chemical modification of already effective inhibitors based upon the structure and residues of the substrate-binding site of the enzymes to further enhance their bactericidal activity against Lyme disease spirochaetes in the future.
Funding
This work was supported by a pilot grant from the National Research Fund for Tick-borne Diseases and a chapter grant (New Jersey) from the Arthritis Foundation to N. P., and the Idaho IDeA programme (NIH P20RR016454), a pilot grant from the Mountain States Tumor and Medical Research Institute (MSTMRI) and the Boise State University Faculty Research programme to K. A. C.
J. A. M. was supported by an undergraduate premedical research fellowship from MSTMRI.
Transparency declarations
None to declare.
All studies involving Lyme spirochaetes were conducted by N. P. and her student S. P., and all kinetic analyses were carried out by K. A. C. and J. A. M. (his student). K. A. C. also conducted structural modelling of B. burgdorferi enzymes. N. P. and K. A. C. wrote the article.
Acknowledgements
We thank Karl Drlica for careful review of the manuscript prior to submission.
References
- 1.Wormser GP, Dattwyler RJ, Shapiro ED, et al. Single-dose prophylaxis against Lyme disease. Lancet Infect Dis. 2007;7:371–3. doi: 10.1016/S1473-3099(07)70117-2. [DOI] [PubMed] [Google Scholar]
- 2.Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43:1089–134. doi: 10.1086/508667. [DOI] [PubMed] [Google Scholar]
- 3.Jackson CR, Boylan JA, Frye JG, et al. Evidence of a conjugal erythromycin resistance element in the Lyme disease spirochete Borrelia burgdorferi. Int J Antimicrob Agents. 2007;30:496–504. doi: 10.1016/j.ijantimicag.2007.07.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Sufrin JR, Meshnick SR, Spiess AJ, et al. Methionine recycling pathways and antimalarial drug design. Antimicrob Agents Chemother. 1995;39:2511–5. doi: 10.1128/aac.39.11.2511. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Duerre JA. A hydrolytic nucleosidase acting on S-adenosylhomocysteine and on 5′-methylthioadenosine. J Biol Chem. 1962;237:3737–41. [Google Scholar]
- 6.Chen X, Schauder S, Potier N, et al. Structural identification of a bacterial quorum-sensing signal containing boron. Nature. 2002;415:545–9. doi: 10.1038/415545a. [DOI] [PubMed] [Google Scholar]
- 7.Schauder S, Bassler BL. The languages of bacteria. Genes Dev. 2001;15:1468–80. doi: 10.1101/gad.899601. [DOI] [PubMed] [Google Scholar]
- 8.Winzer K, Hardie KR, Williams P. Bacterial cell-to-cell communication: sorry, can't talk now—gone to lunch! Curr Opin Microbiol. 2002;5:216–22. doi: 10.1016/s1369-5274(02)00304-1. [DOI] [PubMed] [Google Scholar]
- 9.Gianotti AJ, Tower PA, Sheley JH, et al. Selective killing of Klebsiella pneumoniae by 5-trifluoromethylthioribose. Chemotherapeutic exploitation of the enzyme 5-methylthioribose kinase. J Biol Chem. 1990;265:831–7. [PubMed] [Google Scholar]
- 10.Singh V, Lee JE, Nunez S, et al. Transition state structure of 5′-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Escherichia coli and its similarity to transition state analogues. Biochemistry. 2005;44:11647–59. doi: 10.1021/bi050863a. [DOI] [PubMed] [Google Scholar]
- 11.Li X, Chu S, Feher VA, et al. Structure-based design, synthesis, and antimicrobial activity of indazole-derived SAH/MTA nucleosidase inhibitors. J Med Chem. 2003;46:5663–73. doi: 10.1021/jm0302039. [DOI] [PubMed] [Google Scholar]
- 12.Schramm VL, Gutierrez JA, Cordovano G, et al. Transition state analogues in quorum sensing and SAM recycling. Nucleic Acids Symp Ser (Oxf) 2008;52:75–6. doi: 10.1093/nass/nrn038. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Lee JE, Settembre EC, Cornell KA, et al. Structural comparison of MTA phosphorylase and MTA/AdoHcy nucleosidase explains substrate preferences and identifies regions exploitable for inhibitor design. Biochemistry. 2004;43:5159–69. doi: 10.1021/bi035492h. [DOI] [PubMed] [Google Scholar]
- 14.Lee JE, Cornell KA, Riscoe MK, et al. Structure of E. coli 5′-methylthioadenosine/S-adenosylhomocysteine nucleosidase reveals similarity to the purine nucleoside phosphorylases. Structure (Camb) 2001;9:941–53. doi: 10.1016/s0969-2126(01)00656-6. [DOI] [PubMed] [Google Scholar]
- 15.Lee JE, Singh V, Evans GB, et al. Structural rationale for the affinity of pico- and femtomolar transition state analogues of Escherichia coli 5′-methylthioadenosine/S-adenosylhomocysteine nucleosidase. J Biol Chem. 2005;280:18274–82. doi: 10.1074/jbc.M414471200. [DOI] [PubMed] [Google Scholar]
- 16.Pajula RL, Raina A. Methylthioadenosine, a potent inhibitor of spermine synthase from bovine brain. FEBS Lett. 1979;99:343–5. doi: 10.1016/0014-5793(79)80988-6. [DOI] [PubMed] [Google Scholar]
- 17.Raina A, Tuomi K, Pajula RL. Inhibition of the synthesis of polyamines and macromolecules by 5′-methylthioadenosine and 5′-alkylthiotubercidins in BHK21 cells. Biochem J. 1982;204:697–703. doi: 10.1042/bj2040697. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Borchardt RT, Creveling CR, Ueland PM. Biological Methylation and Drug Design. Clifton, NJ: Humana Press; 1986. [Google Scholar]
- 19.von Lackum K, Babb K, Riley SP, et al. Functionality of Borrelia burgdorferi LuxS: the Lyme disease spirochete produces and responds to the pheromone autoinducer-2 and lacks a complete activated-methyl cycle. Int J Med Microbiol. 2006;296(Suppl 40):92–102. doi: 10.1016/j.ijmm.2005.12.011. [DOI] [PubMed] [Google Scholar]
- 20.Singh V, Shi W, Almo SC, et al. Structure and inhibition of a quorum sensing target from Streptococcus pneumoniae. Biochemistry. 2006;45:12929–41. doi: 10.1021/bi061184i. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Babb K, von Lackum K, Wattier RL, et al. Synthesis of autoinducer 2 by the Lyme disease spirochete, Borrelia burgdorferi. J Bacteriol. 2005;187:3079–87. doi: 10.1128/JB.187.9.3079-3087.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Riley SP, Bykowski T, Babb K, et al. Genetic and physiological characterization of the Borrelia burgdorferi ORF BB0374-pfs-metK-luxS operon. Microbiology. 2007;153:2304–11. doi: 10.1099/mic.0.2006/004424-0. [DOI] [PubMed] [Google Scholar]
- 23.Parveen N, Leong JM. Identification of a candidate glycosaminoglycan-binding adhesin of the Lyme disease spirochete Borrelia burgdorferi. Mol Microbiol. 2000;35:1220–34. doi: 10.1046/j.1365-2958.2000.01792.x. [DOI] [PubMed] [Google Scholar]
- 24.Parveen N, Cornell KA, Bono JL, et al. Bgp, a secreted GAG-binding protein of B. burgdorferi strain N40, displays nucleosidase activity and is not essential for infection of immunodeficient mice. Infect Immun. 2006;74:3016–20. doi: 10.1128/IAI.74.5.3016-3020.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Fraser CM, Casjens S, Huang WM, et al. Genomic sequence of a Lyme disease spirochaete Borrelia burgdorferi. Nature. 1997;390:580–6. doi: 10.1038/37551. [DOI] [PubMed] [Google Scholar]
- 26.Roth BL, Poot M, Yue ST, et al. Bacterial viability and antibiotic susceptibility testing with SYTOX green nucleic acid stain. Appl Environ Microbiol. 1997;63:2421–31. doi: 10.1128/aem.63.6.2421-2431.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Langsrud S, Sundheim G. Flow cytometry for rapid assessment of viability after exposure to a quaternary ammonium compound. J Appl Bacteriol. 1996;81:411–8. doi: 10.1111/j.1365-2672.1996.tb03527.x. [DOI] [PubMed] [Google Scholar]
- 28.Singh V, Shi W, Evans GB, et al. Picomolar transition state analogue inhibitors of human 5′-methylthioadenosine phosphorylase and X-ray structure with MT-immucillin-A. Biochemistry. 2004;43:9–18. doi: 10.1021/bi0358420. [DOI] [PubMed] [Google Scholar]
- 29.Singh V, Evans GB, Lenz DH, et al. Femtomolar transition state analogue inhibitors of 5′-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Escherichia coli. J Biol Chem. 2005;280:18265–73. doi: 10.1074/jbc.M414472200. [DOI] [PubMed] [Google Scholar]
- 30.Schwede T, Kopp J, Guex N, et al. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res. 2003;31:3381–5. doi: 10.1093/nar/gkg520. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Arnold K, Bordoli L, Kopp J, et al. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics. 2006;22:195–201. doi: 10.1093/bioinformatics/bti770. [DOI] [PubMed] [Google Scholar]
- 32.Kopp J, Schwede T. The SWISS-MODEL repository of annotated three-dimensional protein structure homology models. Nucleic Acids Res. 2004;32:D230–4. doi: 10.1093/nar/gkh008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Lee JE, Cornell KA, Riscoe MK, et al. Expression, purification, crystallization and preliminary X-ray analysis of Escherichia coli 5′-methylthioadenosine/S-adenosylhomocysteine nucleosidase. Acta Crystallogr D Biol Crystallogr. 2001;57:150–2. doi: 10.1107/s0907444900014669. [DOI] [PubMed] [Google Scholar]
- 34.Montgomery RR, Schreck K, Wang X, et al. Human neutrophil calprotectin reduces the susceptibility of Borrelia burgdorferi to penicillin. Infect Immun. 2006;74:2468–72. doi: 10.1128/IAI.74.4.2468-2472.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Riscoe MK, Ferro AJ, Fitchen JH. Methionine recycling as a target for antiprotozoal drug development. Parasitol Today. 1989;5:330–3. doi: 10.1016/0169-4758(89)90128-2. [DOI] [PubMed] [Google Scholar]
- 36.Cornell KA, Swarts WE, Barry RD, et al. Characterization of recombinant Escherichia coli 5′-methylthioadenosine/S-adenosylhomocysteine nucleosidase: analysis of enzymatic activity and substrate specificity. Biochem Biophys Res Commun. 1996;228:724–32. doi: 10.1006/bbrc.1996.1723. [DOI] [PubMed] [Google Scholar]
- 37.Cornell KA, Winter RW, Tower PA, et al. Affinity purification of 5-methylthioribose kinase and 5-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Klebsiella pneumoniae. Biochem J. 1996;317:285–90. doi: 10.1042/bj3170285. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Lee JE, Smith GD, Horvatin C, et al. Structural snapshots of MTA/AdoHcy nucleosidase along the reaction coordinate provide insights into enzyme and nucleoside flexibility during catalysis. J Mol Biol. 2005;352:559–74. doi: 10.1016/j.jmb.2005.07.027. [DOI] [PubMed] [Google Scholar]
- 39.Siu KK, Lee JE, Smith GD, et al. Structure of Staphylococcus aureus 5′-methylthioadenosine/S-adenosylhomocysteine nucleosidase. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2008;64:343–50. doi: 10.1107/S1744309108009275. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Lee JE, Cornell KA, Riscoe MK, et al. Structure of Escherichia coli 5′-methylthioadenosine/S-adenosylhomocysteine nucleosidase inhibitor complexes provide insight into the conformational changes required for substrate binding and catalysis. J Biol Chem. 2003;278:8761–70. doi: 10.1074/jbc.M210836200. [DOI] [PubMed] [Google Scholar]